Author(s): Moshe Talpaz, John Mascarenhas, Ronald Hoffman Abstract: P 699 Session topic: 16. Myeloproliferative neoplasms – Clinical Background: MF is a life-threatening hematologic malignancy characterized by splenomegaly, debilitating constitutional symptoms, and progressive cytopenias. The approved JAK inhibitor ruxolitinib reduces splenomegaly and symptoms in pts with MF, but is associated with dose-limiting cytopenias...
Pro zobrazení tohoto obsahu je třeba být přihlášen.